Table 1 Main characteristics of the studies included in the meta-analysis
References | Country | Design | Sample size | Follow up (months) | Outcome | |
|---|---|---|---|---|---|---|
Statin | Placebo | |||||
Abisi et al. [8] | UK | Cohort | 21 | 61 | 1 | MMP-9 levels |
Evans et al. [15] | UK | Cohort | 7 | 10 | 1 | MMP-9 levels |
Hurks et al. [16] | Netherlands | Cohort | 135 | 81 | 1 | MMP-9 levels |
Karrowni et al. [2] | US | Cohort | 136 | 75 | 12 | Growth rate |
Mosorin et al. [5] | Finland | Cohort | 34 | 87 | 42 | Growth rate |
O’Donell et al. [17] | US | Cohort | 25,997 | 11,941 | 36 | Aneurysm size |
Raux et al. [18] | France | Cohort | 120 | 46 | 24 | Aneurysm size |
Stein et al. [19] | US | Cohort | 368 | 1184 | NR | Aneurysm size and growth rate |
Sukhija et al. [20] | US | Cohort | 75 | 55 | 24 | Aneurysm size |
Wilson et al. [21] | UK | Cohort | 17 | 46 | NR | MMP-9 levels |